Wainwright reiterates Buy on Vanda stock after sleep disorder trial

Vanda reported positive Phase 3 results for HETLIOZ in delayed sleep-wake phase disorder: sleep onset shifted 42.5 minutes earlier versus 5.4 minutes on placebo, a 37.1-minute difference; 60% of treated participants advanced timing by at least 30 minutes versus 15% on placebo. The company plans to discuss the data with the FDA and seek supplemental approval, which would make HETLIOZ the first FDA-approved medicine for the condition if approved. Results are offset by a Q2 2026 adjusted loss of $1.04 per share versus the expected $0.60 loss and revenue of $50.5 million versus $61.8 million expected; H.C. Wainwright maintained Buy but cut its target from $21 to $20.

Analysis

The trial result adds asset-level optionality, but it does not yet resolve Vanda’s more immediate commercial and funding questions. The enrolled DSWPD cohort was small and treatment brief; FDA feedback on endpoint sufficiency, durability, and the proposed label matters more than the “first approved” framing. Prevalence is not a revenue forecast: diagnosis rates, willingness to use a drug for circadian disorders, payer coverage, and competition from behavioral interventions could sharply narrow the addressable market. An expanded indication may also slow HETLIOZ’s decline without reversing it; verify prescription trends and whether the reported shipment timing explains any subsequent-quarter revenue rather than treating it as a clean rebound.

Near term, expect volatility around FDA interaction and sNDA filing. Over 1–3 months, FDA alignment on the existing package is the key de-risking catalyst; a request for another study would defer value and increase the importance of cash runway. Over 6–18 months, approval would still require launch investment and evidence of physician adoption, while weak legacy-product sales and recent operating underperformance could constrain the company’s ability to fund that effort. The contrarian point: “first approved” can attract attention, but does not establish a large, rapidly penetrated market. Conversely, the trial may be undervalued if FDA accepts the package and investors are overly anchored to one weak quarter. Cash, burn, patent/exclusivity, and detailed trial data are missing; do not infer valuation or financing risk without them.

Key Decisions for Investors

• No immediate directional position: wait for FDA meeting feedback and confirmation that the company has a credible sNDA path. Consider a small, staged VNDA long only after FDA alignment; invalidate the thesis if FDA requires a new pivotal study or the submission is delayed materially.
• Treat the approximately $7 million shipment timing explanation as unverified until the next report: check recognized revenue, HETLIOZ prescriptions, and channel inventory before interpreting a sequential improvement as demand recovery.
• Before sizing any position, review cash, quarterly cash burn, debt/obligations, patent and exclusivity runway, and expected launch costs. If runway is short relative to the regulatory timeline, avoid owning unhedged catalyst exposure.
• For a 6–18 month bull case, track label breadth, payer access, and early prescriber uptake—not prevalence estimates or analyst targets. Weak uptake despite approval, or continued HETLIOZ erosion, would falsify the commercial-expansion thesis.